OBJECTIVES: Studies have shown similar clinical cure rates and shorter length of stay (LOS) for linezolid compared to vancomycin in patients with complicated skin and soft tissue infections (cSSTI) due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). This study examined the clinical and economic consequences of using linezolid vs. vancomycin from the French health system perspective. METHODS: A decisionanalytic model followed an average patient from initiation of empiric treatment until successful 1st-line treatment, death, or 2nd-line treatment failure. Efficacy data were derived from published clinical trials. Resource utilization patterns were collected through structured interviews with 4 French physicians experienced in treating cSSTI. Costs from official price and tariff lists were applied to antibiotics therapy, hospitalisation (by ward type), isolation, tests, adverse events, and post-discharge. Patients could be discharged to oral linezolid. The base case used therapy duration and LOS from the expert panel. Outcomes included total cost per patient, and cost per cure. RESULTS: Average total cost per episode was €7784 for linezolid vs. €8514 for vancomycin (cost savings of €730 mostly due to reduction in hospitalization costs from earlier discharge). Mean LOS after two lines of treatment was 10.7 days for linezolid vs. 13.3 days for vancomycin. An additional 0.5% of patients treated with linezolid (98.5%) vs. vancomycin (98.0%) were cured. Slight increase in effectiveness and reduced cost made linezolid the dominant treatment strategy. One-way sensitivity analysis on selected parameters (50% variation above or below baseline), and a conservative scenario with simultaneous changes in key parameters, did not change the overall conclusions (linezolid remained cost-saving). CONCLUSION: This model showed that linezolid could be cost saving when treating patients with cSSTI due to suspected MRSA, while overall clinical cure was similar. Linezolid could therefore be considered an efficient strategy for treating cSSTI in France.
PIN13

COST-EFFECTIVENESS OF LINEZOLID VS.VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
De Cock E 1 , Timsit JF 2 , Carlet J 3 , Leroy O 4 , Wolff M 5 , Levrat F 6 1 United BioSource Corporation, Barcelona, Spain, 2 Hôpital Albert Michallon, Grenoble, France, 3 Groupe Hospitalier Paris Saint Joseph, Paris, France, 4 Hôpital Guy Chatiliez, Tourcoing, France, 5 Hôpital Bichat Claude Bernard, Paris, France, 6 Pfizer, Paris, France OBJECTIVES: Linezolid has demonstrated improved survival and clinical cure rates in hospitalised patients with nosocomial pneumonia (NP) caused by known or suspected methicillinresistant Staphylococcus aureus (MRSA). This study assessed the cost-effectiveness of linezolid vs. vancomycin from the perspective of the French health system. METHODS: A decisionanalytic model followed an average patient from initiation of empiric treatment until successful 1st-line treatment, death, or 2nd-line treatment failure. Efficacy data were derived from published clinical trials. Five French physicians experienced in treating NP provided resource utilization data through structured interviews. Costs from official price and tariff lists were applied to antibiotic therapy, hospitalisation (by ward type), isolation, tests, and adverse events. The model applied similar length of successful 1st-line treatment for linezolid and vancomycin. The model base case conservatively assumed that length of stay was equal to therapy duration. Outcomes included total cost per patient, cost per cure, cost per death avoided, and cost per life year gained. RESULTS: An additional 7.6% of patients treated with linezolid (70.9%) vs. vancomycin (63.2%) were cured. Average total cost per episode was €16,732 for linezolid vs. €15,375 for vancomycin, Modelled survival was 80.4% (linezolid) vs. 69.7% (vancomycin), resulting in an average 2.0 life-years gained per linezolid patient in a 65-year-old cohort (14.9 vs. 13.0 years). Costs per life-year gained (excluding future costs) and death avoided were €685 and €12,727, respectively. One-way sensitivity analysis on selected parameters (50% variation above or below baseline) did not change the overall conclusions. CONCLUSION: Improved clinical outcomes, but increased cost per episode were calculated for linezolid-treated patients. The results suggest that linezolid can be considered a cost-effective alternative for treating patients with NP due to suspected MRSA in France.
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COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN
León C 1 , Gómez Mateos JM 1 , Catalá R 2 ,Vázquez MJ 2 , Alvarez Rocha L 3 , Nájera MD 4 , Rubio-Terrés C 5 , García M 6 , Escudero López-Cepero E 6 1 Hospital Universitario de Valme, Sevilla, Spain, 2 Hospital General de Móstoles, Madrid, Spain, 3 Complejo Hospitalario Juan Canalejo, La Coruña, Spain, 4 Hospital Universitario Morales Meseguer, Murcia, Spain, 5 Health Value, Madrid, Spain, 6 Pfizer Spain, Madrid, Spain OBJECTIVES: Linezolid has shown efficacy in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, including nosocomial pneumonia (NP). In patients with MRSA-NP, survival and clinical cure rate was higher for patients treated with linezolid (80% and 59%, respectively) than those treated with vancomycin (63.5% and 35.5%, respectively). The objective of this study is to asses the economic impact of these clinical outcomes in the Spanish setting. METHODS: A retrospective decision-analytical model from the hospital perspective was applied to pooled data from 2 prospective, randomized, controlled-double-blind studies. The model described possible treatment outcomes for patients beginning empiric MRSA-NP treatment. Clinical and other parameters were obtained from published trials and from an expert panel, comprised of 5 Spanish experts experienced in treating NP. Resource use was estimated by the expert panel. Only direct costs (€2007) were considered. The model assumed 50% of suspected MRSA patients had proven MRSA. Model outputs included costs/ patient, cost/death avoided, cost/life-year gained (LYG), and cost/ cure. Sensitivity analyses were carried out to test the robustness of the model. RESULTS: The overall clinical cure rate was 11% greater for linezolid than for vancomycin (71% versus 60%). Average total treatment cost was €16,602 for linezolid versus €15,823 for vancomycin-treated patients; incremental cost €6829. Death rates were 21% (linezolid) versus 34% (vancomycin), with an average 1.9 LYG per linezolid patient in a 65-year-Abstracts A439 old cohort (13.6 vs. 11.3 years). The incremental costs/LYG and death avoided were €406 and €4730, respectively. Although the model was sensitive to variables like proven MRSA percentage and costs accrued by patients who die, varying these parameters by 25% the overall conclusions remained the same. CONCLU-SION: According to this model, Linezolid is cost-effective versus vancomycin for MRSA suspected-nosocomial pneumonia in Spain, with and additional cost/LYG and death avoided below the acceptable threshold. 
RESULTS:
Randomized head-to-head clinical trial of Augmentin ES® vs conventional Augmentin® was found and significant difference in clinical cure rate between two drugs was revealed: 84.1% vs 78.8%, respectively; no significant differences in safety profile were found. Cost analysis revealed that savings per patient when Augmentin ES® is used in place of conventional Augmentin® were: PLN28.27 (€7.4) (public payer) and PLN27.9 (€7.3) (payer). Results of clinical and cost analysis proved that conventional Augmentin® therapy is dominated by Augmentin ES®. The results proved to be robust to variations in the drugs cost acquired in sensitivity analysis. Savings accompanying clinical cure of one patient in case of Augmentin ES® used in place of Augmentin® were: PLN533.4 (€140.3) (public payer perspective) and PLN526.4) (€138.5) (payer perspective). CONCLU-SION: Augmentin ES® compared with conventional therapy brings significant savings and is a cost-effective treatment of acute otitis media in Poland.
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COST-EFFECTIVENESS OF AUGMENTIN ES® VS AZITHROMYCIN FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND
Kawalec P 1 , Cel M 2 , Glogowski C 2 1 Centrum HTA, Kraków, Poland, 2 GSK Commercial Sp. z o.o, Warsaw, Poland OBJECTIVES: To assess clinical effectiveness and costs of Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in two divided doses) vs azithromycin (10 mg/kg, day 1; 5 mg/kg/d, days 2-5) in acute otitis media treatment in Poland from the public payer (NHF) and payer (NHF + patient) perspective.
METHODS:
Systematic review according to Cochrane Collaboration guidelines and clinical effectiveness analysis according to Polish HTA Guidelines were performed. Medline (Pubmed) Cochrane and EMBASE were searched (August 2006) . Only RCTs with high credibility assessment (based on Jadad scale) were included in the systematic review. Overall costs of treatment were taken into account, including cost of pharmacotherapy, drug administration, second-line therapy, complications of otitis media and adverse events. Sensitivity analysis was performed according to a range of acquisition costs of Augmentin ES® and azithromycin (+/-20%). All calculations were performed for 2006 (€1 = PLN3.8). RESULTS: Randomized head-to-head clinical trial of Augmentin ES® vs azithromycin was found and significant difference in clinical cure rate between two drugs was revealed: 90.5% vs 80.9%, respectively; no significant differences in safety profile were found. Cost analysis revealed that savings per patient when Augmentin ES® is used in place of azithromycin were: PLN49 (€12.9) (public payer) and PLN38.3 PLN (€10.1) (payer). Results of clinical and cost analysis proved that azithromycin therapy is dominated by Augmentin ES®. The results proved to be robust to variations in the drugs cost acquired in sensitivity analysis. Savings accompanying clinical cure of one patient in case of Augmentin ES® used in place of azithromycin were: PLN510.5 (€134.3) (from public payer perspective) and PLN399.2 (€105) (payer perspective). CONCLU-SION: Augmentin ES® compared with azithromyycin therapy brings significant savings and is a cost-effective treatment of acute otitis media in Poland.
PIN17 ESTIMATING THE LONG-TERM HEALTH AND ECONOMIC IMPACT OF A PROPHYLACTIC CERVICAL CANCER VACCINE ON THE BURDEN OF CERVICAL DISEASE IN ITALY
Ferko N 1 , Debicki D 1 , Bamfi F 2 , Marocco A 2 , Mantovani LG 3 1 i3 Innovus Research Inc, Burlington, ON, Canada, 2 GlaxoSmithKline Spa, Verona, Veneto, Italy, 3 University of Naples, Federico II, Naples, Italy OBJECTIVES: HPV epidemiology and screening practices vary considerably between countries and specific analyses are required to estimate the impact of prophylactic cervical cancer vaccination. This study adapted a health economic model to Italy to predict the clinical and economic impact. METHODS: A Markov model based upon the natural history of HPV and cervical cancer was developed to simulate transitions between health states (normal, HPV, Cervical Intraepithelial Neoplasia stages 1 to 3, Cervical Cancer (CC) stages 1 to 4, and death) in the presence of specific screening programs. Italian data was used to for costs, and screening and treatment practices, and published clinical data was used to estimate efficacy against oncogenic HPV types 16, 18, 31, 45. The model was calibrated to Italian epidemiological data including age-specific HPV prevalence, prevalence of CIN lesions, CC incidence and mortality. The cost-effectiveness of vaccination against HPV for cohorts of different ages was assessed using the calibrated model. RESULTS: With 100% vaccine coverage, in a 12 year old cohort of females there is estimated to be a 68% reduction in the prevalence of high-grade precancerous lesions due to oncogenic HPV, and a 78% and 79% reduction in cervical cancer cases and deaths, respectively. Vaccination would also produce substantial reductions in these outcomes for the 18 and 25 year old cohorts, and in the number of screening tests and treatments required. With 3% discount rates on costs and outcomes, vaccination is cost effective in cohorts of 12, 18, and 25 year olds with estimated cost per QALYs of €30,624, €31,078, and €31,116 respectively. CONCLUSION: The model was successfully adapted to represent Italian epidemiological data, screening
